Neogen CorpNEOG

Neogen Corporation, the Lansing, Michigan outfit that likes to describe itself as dedicated to food and animal safety, filed its latest 10-Q on 9 April 2026 and delivered a set of numbers that read like a safety drill gone wrong: revenue of $211.2 million for the quarter ended 28 February 2026, down 4.4% year-over-year, with a net loss of $17.0 million and an operating loss of $3.3 million. Core revenue, which strips out currency moves and recent divestitures, eked out a 0.1% increase, a figure that sounds less like growth and more like a flatline with a pulse. The company’s Animal Safety segment-home to veterinary instruments, vaccines, topicals, parasiticides, diagnostic products, biosecurity gear, and genomics testing services-is the beating heart of the business, yet the heartbeat looks suspiciously arrhythmic. (source: NEOG 10-Q, period ending 2026-02-28, https://www.sec.gov/Archives/edgar/data/711377/000119312526149599/neog-20260228.htm)

What Neogen actually does is sell a sprawling catalogue of products and services aimed at keeping food chains and animal health intact: think pathogen detection, animal pharmaceuticals, and genomic tools that promise to make farms and food processors safer. The company’s pitch deck leans hard into the idea of a safer, smarter world, but the filed numbers suggest that safer and smarter might not be the same thing as profitable. The Animal Safety segment is the flagship, yet its headline revenue decline and shrinking operating margin tell a story that the glossy slides don’t: the business is still fighting the after-effects of divestitures, currency headwinds, and a cost base that’s proving harder to trim than a vet’s overgrown poodle. (source: NEOG 10-Q, period ending 2026-02-28, https://www.sec.gov/Archives/edgar/data/711377/000119312526149599/neog-20260228.htm)

The balance sheet shows assets of $3.36 billion against liabilities of $1.26 billion, leaving $2.10 billion in shareholders’ equity, a cushion that looks thicker than a vet’s lab coat until you notice the cash position is only $159.9 million and operating cash flow for the quarter was $53.0 million. Research and development spend clocked in at $3.8 million, a figure that sounds modest until you remember the company’s R&D budget is supposed to be turning out the next generation of safety products. Inventory, meanwhile, fell by $21.5 million, a decline that could mean leaner shelves or it could mean products that aren’t moving-a distinction the filings leave unexamined. Diluted EPS came in at -$0.08 on 217.7 million shares, a line item that turns red every time a slide deck tries to paint the future in green. (source: NEOG 10-Q, period ending 2026-02-28, https://www.sec.gov/Archives/edgar/data/711377/000119312526149599/neog-20260228.htm)

Neogen’s April 2026 press release cheerfully announced a raised fiscal 2026 revenue outlook and maintained adjusted EBITDA guidance, two lines that sit awkwardly beside the same document’s admission that core revenue rose just 0.1% after adjusting for currency and divestitures. The company’s 13G filing shows a large holder at 11.5%, a stake big enough to keep the board engaged but not large enough to trigger a bid, while the 144 filings in late May and early June suggest insiders are still willing to sell shares into the market. The polished language in the press release contrasts sharply with the raw data in the 10-Q, leaving investors to decide whether to trust the story or the numbers. (source: Press Release, 2026-04-09, https://www.sec.gov/Archives/edgar/data/711377/000119312526148851/neog-ex99_1.htm; NEOG 13G, 2026-07-07, https://www.sec.gov/Archives/edgar/data/711377/000146510926000054/xslSCHEDULE_13G_X02/primary_doc.xml; NEOG 144, 2026-06-03, https://www.sec.gov/Archives/edgar/data/711377/000195917326004307/xsl144X01/primary_doc.xml; NEOG 144, 2026-05-29, https://www.sec.gov/Archives/edgar/data/711377/000195917326004139/xsl144X01/primary_doc.xml)

If you want to see where the rubber meets the road, the company’s 10-Q is the place to look, and it offers more questions than answers. The conflict minerals report, filed on 20 May 2026, ticks the corporate sustainability box but says nothing about the $21.5 million inventory drawdown or the $3.3 million operating loss. The 11-K, meanwhile, confirms a defined contribution plan for employees, a benefit that’s standard in corporate America but feels like small comfort when the operating business is still in the red. The evidence we have is clear: Neogen is a real business with real products, real customers, and a real cash position, but the numbers also show a company that’s still working off the fumes of its past and hoping its R&D pipeline will deliver the next big hit. Until that happens, the polished story will keep running while the balance sheet keeps running on empty. (source: NEOG SD, 2026-05-20, https://www.sec.gov/Archives/edgar/data/711377/000119312526232020/conflict_minerals_2025_v.htm; NEOG 11-K, 2026-06-25, https://www.sec.gov/Archives/edgar/data/711377/000119312526282997/neog-20251231.htm)